Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 2:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dorzolamide-timolol Clear all
Terminated Phase 4 Interventional Accepts healthy volunteers

How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?

NCT06369077
View directory record Official record
Conditions
Glaucoma, Open-Angle, Glaucoma; Drugs
Interventions
dorzolamide/timolol
Drug
Lead sponsor
CT Glaucoma Associates
Other
Eligibility
25 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Norwalk, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Sep 4, 2026, 2:54 PM EDT
Completed Phase 4 Interventional

Lumigan Versus Cosopt

NCT00273455
View directory record Official record
Conditions
Open-Angle Glaucoma
Interventions
bimatoprost 0.03%, dorzolamide 2%/timolol maleate 0.5% fixed combination, placebo
Drug
Lead sponsor
Pharmaceutical Research Network
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Louisville, Kentucky • Mt. Pleasant, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2008 · Synced Sep 4, 2026, 2:54 PM EDT
Completed Phase 4 Interventional Results available

Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma

NCT00869141
View directory record Official record
Conditions
Glaucoma
Interventions
glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 85 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 29, 2015 · Synced Sep 4, 2026, 2:54 PM EDT
Completed Phase 4 Interventional Results available

Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow

NCT00811850
View directory record Official record
Conditions
Glaucoma
Interventions
fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution, fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
30 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 4, 2026, 2:54 PM EDT
Completed Phase 4 Interventional Results available

Effect of Myocilin Genetic Variants on Intraocular Pressure and Pressure Variation in Sitting and Supine Positions

NCT00906087
View directory record Official record
Conditions
Glaucoma
Interventions
Cosopt (combination eyedrop of dorzolamide and timolol)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Sep 4, 2026, 2:54 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration

NCT03034772
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Interventions
Dorzolamide-timolol, Artificial tears
Drug · Other
Lead sponsor
Wills Eye
Other
Eligibility
45 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Palo Alto, California • Boston, Massachusetts • Royal Oak, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Sep 4, 2026, 2:54 PM EDT
Completed Phase 4 Interventional

Cosopt Versus Xalatan

NCT00273429
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
timolol maleate 0.5%, dorzolamide/timolol maleate fixed combination, latanoprost 0.005%, placebo
Drug
Lead sponsor
Pharmaceutical Research Network
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
2
States / cities
Lakeland, Florida • Bourbonnais, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 8, 2007 · Synced Sep 4, 2026, 2:54 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The International Collaborative Exfoliation Syndrome Treatment Study

NCT00804115
View directory record Official record
Conditions
Exfoliation Syndrome, Glaucoma, Ocular Hypertension
Interventions
Latanoprost with Pilocarpine vs Timolol or Cosopt
Drug
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
50 Years to 80 Years
Enrollment
277 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2008 · Synced Sep 4, 2026, 2:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effectiveness and Safety of Timolol and Dorzolamide Loaded Contact Lenses

NCT02852057
View directory record Official record
Conditions
Glaucoma
Interventions
timolol maleate and dorzolamide hydrochloride
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Sep 4, 2026, 2:54 PM EDT
Completed Not applicable Interventional Results available

The Effect of Glaucoma Drops on of the Duration of a Pure Intraocular Gas Bubble

NCT01843920
View directory record Official record
Conditions
Scleral Buckling
Interventions
Timolol-dorzolamide (Glaucoma drops), standard post-operative topical drops
Drug
Lead sponsor
Jason Hsu, MD
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Sep 4, 2026, 2:54 PM EDT
Completed Phase 4 Interventional

Assessing Cosopt Switch Patients

NCT00273442
View directory record Official record
Conditions
Ocular Hypertension, Open-Angle Glaucoma, Exfoliation Syndrome, Glaucoma, Pigmentary
Interventions
timolol maleate, dorzolamide/timolol maleate fixed combination
Drug
Lead sponsor
Pharmaceutical Research Network
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
5
States / cities
Little Rock, Arkansas • Atlanta, Georgia • Bourbonnais, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2008 · Synced Sep 4, 2026, 2:54 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Stop Retinal Ganglion Cell Dysfunction Study

NCT02390284
View directory record Official record
Conditions
Glaucoma
Interventions
Latanoprost, Bimatoprost, Travoprost, Timolol, Dorzolamide, Brinzolamide, Acetazolamide, Methazolamide
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Sep 4, 2026, 2:54 PM EDT
Completed No phase listed Observational Results available

Trusopt and Cosopt; Ocular Perfusion Pressure and Blood Flow: New Long-term Prospective Data

NCT01145898
View directory record Official record
Conditions
Glaucoma
Interventions
(Cosopt®, prostaglandin)
Drug
Lead sponsor
Indiana University
Other
Eligibility
30 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 21, 2014 · Synced Sep 4, 2026, 2:54 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Circadian Rhythms of Aqueous Humor Dynamics in Humans

NCT00572936
View directory record Official record
Conditions
Glaucoma
Interventions
Latanoprost, Dorzolamide, Timolol
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Sep 4, 2026, 2:54 PM EDT
Not listed Not applicable Interventional

Comparison of Efficacy of Two Groups of Glaucoma Drops (Xalatan vs.Cosopt) in Reducing Eye Pressure Following Laser (SLT)Treatment in the Management of Glaucoma.

NCT00440336
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Cosopt, Xalatan
Drug
Lead sponsor
Advanced Glaucoma Specialists
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Reading, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 28, 2007 · Synced Sep 4, 2026, 2:54 PM EDT
Completed Not applicable Interventional Results available

Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy

NCT01257698
View directory record Official record
Conditions
Macular Hole, Retinal Detachment
Interventions
Dorzolamide 2%-timolol 0.5% topical eyedrops
Drug
Lead sponsor
Mid Atlantic Retina
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 4, 2026, 2:54 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost

NCT06883123
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Simbrinza 0.2%-1% Ophthalmic Suspension, Rocklatan 0.02%-0.005% Ophthalmic Solution, Cosopt PF 2%-0.5% Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution
Drug
Lead sponsor
Prairie Eye Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Sep 4, 2026, 2:54 PM EDT
Completed Phase 2 Interventional Results available

Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.

NCT02571972
View directory record Official record
Conditions
Wet Macular Degeneration, Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions
Dorzolamide-timolol
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Sep 4, 2026, 2:54 PM EDT
Completed Not applicable Interventional Results available

Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)

NCT00824824
View directory record Official record
Conditions
Glaucoma
Interventions
Dorzolamide 2%-timolol 0.5%, Brimonidine 0.2%-0.5% timolol 0.5
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
40 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 4, 2026, 2:54 PM EDT